NCT02418793View on ClinicalTrials.gov

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

September 30, 2018

Study Completion Date

September 30, 2018

Conditions
Hemophilia AHemophilia B
Interventions
DRUG

MOD-5014

Long Acting Factor VIIa

Trial Locations (11)

90027

Children's Hospital Los Angeles, Los Angeles

Unknown

City of Hope, Duarte

Orthopaedic Hemophilia Treatment Center, Los Angeles

University of California Davis Medical Center, Sacramento

Rush University Medical Center, Chicago

Bleeding & Clotting Disorders Institute, Peoria

Indiana Hemophilia & Thrombosis Center, Indianapolis

Penn State Milton S. Hershey Medical Center, Hershey

UPMC Presbyterian Shadyside, Pittsburgh

UT Southwestern Medical Center, Dallas

The Gulf States Hemophilia and Thrombophilia Center, Houston

All Listed Sponsors
lead

OPKO Health, Inc.

INDUSTRY

NCT02418793 - A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B | Biotech Hunter | Biotech Hunter